Page last updated: 2024-09-04
jte 522 and isoxazoles
jte 522 has been researched along with isoxazoles in 1 studies
Compound Research Comparison
| Studies (jte 522) | Trials (jte 522) | Recent Studies (post-2010) (jte 522) | Studies (isoxazoles) | Trials (isoxazoles) | Recent Studies (post-2010) (isoxazoles) |
|---|---|---|---|---|---|
| 61 | 1 | 7 | 8,633 | 900 | 3,337 |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Amano, H; Hayashi, I; Inukai, M; Kamata, M; Kitasato, H; Majima, M; Yoshida, S; Yoshimura, H | 1 |
Other Studies
1 other study(ies) available for jte 522 and isoxazoles
| Article | Year |
|---|---|
COX-2/VEGF-dependent facilitation of tumor-associated angiogenesis and tumor growth in vivo.
Topics: Animals; Antibodies, Blocking; Aspirin; Benzenesulfonates; Carcinoma, Lewis Lung; Cyclooxygenase Inhibitors; Disease Models, Animal; Endothelial Growth Factors; Intercellular Signaling Peptides and Proteins; Isoxazoles; Lymphokines; Male; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Neovascularization, Pathologic; Nitrobenzenes; Oxazoles; Prostaglandin-Endoperoxide Synthases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sarcoma 180; Sulfonamides; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |